# How researchers defined low lean mass at the start of COURAGE

- Article ID: research-396
- Product: Trevogrumab (trevogrumab-1mg-3ml)
- Canonical page: https://heritagebiolabs.com/research-library/articles/396-how-researchers-defined-low-lean-mass-at-the-start-of-courage
- Product collection: https://heritagebiolabs.com/research-library/products/trevogrumab
- Product page: https://heritagebiolabs.com/product/trevogrumab-1mg-3ml
- Reading focus: Mechanisms & biology (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2024, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids held together by peptide bonds. Some recognize other molecules and alter signaling. Trevogrumab is a larger protein antibody that targets myostatin, a regulator of muscle mass. Investigators studied the antibody with semaglutide and examined whether the lean mass results differed in adults who entered the trial with low lean mass. [1, 2]

For the subgroup, the investigators used a scan-based definition involving appendicular lean mass relative to body mass index. Appendicular lean mass estimates lean tissue in the arms and legs. Relating it to a body-size measure changes the question from how much lean tissue a person has to how much they have in relation to their size. That was the imaging criterion used to define the starting subgroup in the sponsor’s report. [1]

The sponsor said the low-lean-mass group showed a greater loss of lean mass with semaglutide alone and numerically greater preservation with the addition of trevogrumab. A numerical pattern in a subgroup can help frame a subsequent study. How precisely the treatment difference can be estimated depends on the number of participants and how the analysis was carried out. The report describes this subgroup analysis as prespecified. [1]

A person’s scan measurement and their ability to walk or exert force are different assessments. The subgroup findings concern the starting imaging criterion and a change in lean mass. They do not establish an effect on disability, daily activities or a clinical diagnosis of sarcopenia. The separate COURAGE registry records the planned endpoints for the investigational combinations. [1, 2]

## Sources

1. Regeneron Pharmaceuticals, Inc. Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss. Sponsor results announcement (publication 2026-10-01). <https://newsroom.regeneron.com/news-releases/news-release-details/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass>
2. Regeneron Pharmaceuticals, Inc. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity. ClinicalTrials.gov (publication 2024-03-07, record updated 2026-09-01). <https://clinicaltrials.gov/study/NCT06299098>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 080 - Trevogrumab and Triptorelin GnRH.docx; article 396; content SHA-256 37f9b86a175383ea604172a2eb783a01613aa240d09fcfc2d34ee406261ffdad.
